Glioblastoma Multiforme Clinical Trials in Birmingham, Alabama

4 studies are recruiting for glioblastoma multiforme in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

    This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-…

    Stage
    Phase 1
    Ages
    3 to 22
    Site
    University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
    Locations
    3 in total
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT03911388 on ClinicalTrials.gov

  2. A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

    The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Alabama Birmingham, Birmingham, Alabama
    Locations
    9 in total
    Run by
    Boston Scientific Corporation

    See if you can join NCT05303467 on ClinicalTrials.gov

  3. Study of Pembrolizumab and M032 (NSC 733972)

    This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and perform the Phase II portion using a Recommended Phase 2 Dose (RP2D) of…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Run by
    University of Alabama at Birmingham

    See if you can join NCT05084430 on ClinicalTrials.gov

  4. Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

    The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    8 in total
    Run by
    Orbus Therapeutics, Inc.

    See if you can join NCT05879367 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.